Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025, for NanoVibronix, Inc. (the "Company"). The Company is a medical device firm focusing on non-invasive biological response-activating devices for wound healing and pain therapy. The reporting period is significantly impacted by the consummation of the ENvue Merger on February 14, 2025, which added ENvue Medical Holdings LLC (focused on enteral feeding devices) as a wholly-owned subsidiary. Additionally, a 1-for-11 reverse stock split was effected on March 13, 2025, to regain compliance with Nasdaq listing requirements.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $1,025,000 | $921,000 |
| Gross Profit | $369,000 | $664,000 |
| Gross Margin | 36% | 72% |
| Net Loss | $(2,495,000) | $(588,000) |
| Operating Cash Flow | $(1,343,000) | $(579,000) |
| Cash Balance (End of Period) | $601,000 | $2,700,000 |
| Total Assets | $44,105,000 | $3,629,000 |
| Total Liabilities | $8,430,000 | $3,002,000 |
| Stockholders' Equity | $35,675,000 | $627,000 |
Note: Total assets and equity increased significantly due to the acquisition of ENvue, which added $33.9 million in goodwill and $5.9 million in intangible assets.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11% to $1.025 million, driven by the inclusion of ENvue's operations post-merger.
- Margin Compression: Gross margin declined from 72% to 36%. Management attributes this to a reduction in wholesale sales prices awarded to a key distributor (Ultra Pain Products, LLC).
- Expense Increases:
- R&D Expenses: Rose 338% to $530,000 due to new product development projects.
- Selling & Marketing: Increased 112% to $349,000, primarily due to ENvue's inclusion.
- G&A Expenses: Increased 42% to $1.342 million, driven by merger-related professional fees and ENvue operations.
- Non-Operating Items: A $623,000 warrant modification expense was recorded related to a securities exchange agreement. Conversely, a $58,000 gain was recognized from the change in fair value of a convertible debenture.
- Balance Sheet Expansion: Total assets grew from $3.6 million to $44.1 million, largely due to the recording of goodwill ($33.9M) and intangible assets ($5.9M) from the ENvue acquisition.
Guidance, Outlook, Risks, and Unusual Items
Liquidity and Going Concern
Management has expressed substantial doubt regarding the Company's ability to continue as a going concern. With a cash balance of $601,000 and negative operating cash flow of $1.343 million for the quarter, the Company does not have sufficient resources to fund operations for the next twelve months. Additional capital raising is required.
Recent Financing and Subsequent Events
- Series G Offering: On May 15, 2025, the Company closed an underwritten public offering of Series G Convertible Preferred Stock and warrants, raising approximately $10 million in gross proceeds.
- Debt Instruments: The Company issued a senior convertible debenture (amended to $1.3 million principal) and holds a secured note from Alpha Capital Anstalt ($2.5 million principal).
- April 2025 Note: ENvue issued a $360,000 promissory note to Alpha Capital Anstalt, guaranteed by the Company.
Risks and Contingencies
- Legal Proceedings: The Company is appealing an arbitration award against Protrade Systems, Inc. for approximately $1.5 million (plus interest, accrued at ~$2.2 million as of March 31, 2025). The appeal is expected to proceed to oral arguments by May 2025.
- Nasdaq Compliance: The Company recently regained compliance with Nasdaq bid price and equity rules following a reverse stock split but remains under a one-year mandatory monitoring period.
- Dilution: The Series X and Series G preferred stock contain anti-dilution provisions that may significantly increase the number of common shares issuable upon conversion.
Investor Verification Checklist
- Capital Adequacy: Verify the net proceeds and terms of the May 2025 Series G offering to assess if the $10 million infusion resolves the "going concern" warning.
- Legal Liability: Monitor the status of the Protrade arbitration appeal, as the accrued liability (~$2.2M) represents a significant portion of current liabilities.
- Dilution Impact: Review the conversion terms of Series X and Series G preferred stock to understand the potential dilution to existing common shareholders.
- Merger Integration: Assess whether the ENvue merger will generate sufficient revenue growth to offset the increased operating expenses and margin compression observed in Q1 2025.
- Debt Covenants: Review the terms of the Alpha Capital Anstalt notes and the convertible debenture for redemption rights triggered by future equity issuances.